Arbex Eyes Global Growth With Suzano, Kimberly-Clark
Arbex, the Kleenex tissue maker, told Reuters it plans to add about 10 percentage points of global market share with a new $3.4 billion joint venture involving Suzano after Kimberly-Clark sold a 51% stake in its international tissue business. Arbex aims for 1-2% annual revenue growth and to raise share from 24-25% toward over 35%, investing $100-120m yearly.
How this was made
The 30-second read
Why it matters
Management’s quantified growth ambition (market share from 24-25% to above 35%), a capex range ($100M-$120M annually), and a cost-efficiency approach (regional procurement, lower plastic, waste reduction) are the key decision-relevant elements for traders assessing medium-term tissue margin and share expectations.
Market read
A completed JV closing plus management’s market-share and investment targets can shift expectations for tissue competition and input-cost risk, though the article lacks near-term financial numbers.
What to watch
No timeframe is given for crossing 35% share, and the article does not provide quantified financial impact (earnings, cash proceeds, or margin targets), which may limit how much the market reprices immediately.
Background
The article describes a June 2025 announcement and this month’s closing of Kimberly-Clark’s sale of a 51% stake in its international tissue business to Suzano, creating a $3.4B joint venture with Arbex.
Ticker impact
Kimberly-Clark finalized a sale of a 51% stake in its international tissue business to Suzano, forming a $3.4B joint venture.
Neutral to slightly positive, depending on how investors value risk reduction versus earnings dilution.
The deal size ($3.4B) and rationale (lower input-cost volatility) are concrete, but the article does not quantify earnings impact, cash proceeds, or timing of financial effects.
Market effects
Highlights competitive pressure in tissue and hygiene, with a stated ambition to push market share above 35% and focus on cost efficiency rather than passing costs to consumers.
Emphasizes Brazil-linked industrial know-how (Suzano) being leveraged for global share gains, potentially affecting competitive dynamics across major consumer markets.
The $3.4B JV and input-cost volatility narrative can influence how investors model pulp and tissue supply-chain risk across regions.
Counterpoint
The parents’ comments that the venture is not a priority raise the risk that investment and execution could lag the stated market-share ambition.
Key entities
- companyArbex
Kleenex maker whose CEO outlines growth and cost strategy tied to the Suzano JV.
- companySuzano
Brazilian pulp giant providing industrial expertise and receiving a 51% stake via the JV.
- companyKimberly-Clark
US consumer goods firm that finalized the sale of a 51% stake in its international tissue business to Suzano.
